94 related articles for article (PubMed ID: 20399844)
1. Antinociceptive activity of Delta9-tetrahydrocannabinol non-ionic microemulsions.
Lazzari P; Fadda P; Marchese G; Casu GL; Pani L
Int J Pharm; 2010 Jun; 393(1-2):238-43. PubMed ID: 20399844
[TBL] [Abstract][Full Text] [Related]
2. Decreased basal endogenous opioid levels in diabetic rodents: effects on morphine and delta-9-tetrahydrocannabinoid-induced antinociception.
Williams J; Haller VL; Stevens DL; Welch SP
Eur J Pharmacol; 2008 Apr; 584(1):78-86. PubMed ID: 18313663
[TBL] [Abstract][Full Text] [Related]
3. Liquid spray formulations of xibornol by using self-microemulsifying drug delivery systems.
Cirri M; Mura P; Mora PC
Int J Pharm; 2007 Aug; 340(1-2):84-91. PubMed ID: 17531411
[TBL] [Abstract][Full Text] [Related]
4. Enhancement mu opioid antinociception by oral delta9-tetrahydrocannabinol: dose-response analysis and receptor identification.
Cichewicz DL; Martin ZL; Smith FL; Welch SP
J Pharmacol Exp Ther; 1999 May; 289(2):859-67. PubMed ID: 10215664
[TBL] [Abstract][Full Text] [Related]
5. The influence of cosurfactants and oils on the formation of pharmaceutical microemulsions based on PEG-8 caprylic/capric glycerides.
Djekic L; Primorac M
Int J Pharm; 2008 Mar; 352(1-2):231-9. PubMed ID: 18068919
[TBL] [Abstract][Full Text] [Related]
6. Effects of RM-beta-CD on sublingual bioavailability of Delta9-tetrahydrocannabinol in rabbits.
Mannila J; Järvinen T; Järvinen K; Tarvainen M; Jarho P
Eur J Pharm Sci; 2005 Sep; 26(1):71-7. PubMed ID: 15955678
[TBL] [Abstract][Full Text] [Related]
7. Development and characterization of self-microemulsifying drug delivery system of tacrolimus for intravenous administration.
Borhade VB; Nair HA; Hegde DD
Drug Dev Ind Pharm; 2009 May; 35(5):619-30. PubMed ID: 18979309
[TBL] [Abstract][Full Text] [Related]
8. Comparative pharmacology of Delta9-tetrahydrocannabinol and its metabolite, 11-OH-Delta9-tetrahydrocannabinol.
Lemberger L; Martz R; Rodda B; Forney R; Rowe H
J Clin Invest; 1973 Oct; 52(10):2411-7. PubMed ID: 4729039
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the Solutol® HS15/water phase diagram and the impact of the Δ9-tetrahydrocannabinol solubilization.
Murgia S; Fadda P; Colafemmina G; Angelico R; Corrado L; Lazzari P; Monduzzi M; Palazzo G
J Colloid Interface Sci; 2013 Jan; 390(1):129-36. PubMed ID: 23099249
[TBL] [Abstract][Full Text] [Related]
10. Synergistic affective analgesic interaction between delta-9-tetrahydrocannabinol and morphine.
Roberts JD; Gennings C; Shih M
Eur J Pharmacol; 2006 Jan; 530(1-2):54-8. PubMed ID: 16375890
[TBL] [Abstract][Full Text] [Related]
11. Modulation of oral morphine antinociceptive tolerance and naloxone-precipitated withdrawal signs by oral Delta 9-tetrahydrocannabinol.
Cichewicz DL; Welch SP
J Pharmacol Exp Ther; 2003 Jun; 305(3):812-7. PubMed ID: 12606610
[TBL] [Abstract][Full Text] [Related]
12. Chronic Delta9-tetrahydrocannabinol treatment produces antinociceptive tolerance in mice without altering protein kinase A activity in mouse brain and spinal cord.
Dalton GD; Smith FL; Smith PA; Dewey WL
Biochem Pharmacol; 2005 Jul; 70(1):152-60. PubMed ID: 15913565
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological profile of delta 9-THC carbamate.
Little PJ; Kaplan NC; Martin BR
Alcohol Drug Res; 1987; 7(5-6):517-23. PubMed ID: 3040025
[TBL] [Abstract][Full Text] [Related]
14. Analgesic activity and pharmacological characterization of N-[1-phenylpyrazol-3-yl]-N-[1-(2-phenethyl)-4-piperidyl] propenamide, a new opioid agonist acting peripherally.
Goicoechea C; Sánchez E; Cano C; Jagerovic N; Martín MI
Eur J Pharmacol; 2008 Oct; 595(1-3):22-9. PubMed ID: 18706410
[TBL] [Abstract][Full Text] [Related]
15. Effects of acute oral Delta9-tetrahydrocannabinol and standardized cannabis extract on the auditory P300 event-related potential in healthy volunteers.
Roser P; Juckel G; Rentzsch J; Nadulski T; Gallinat J; Stadelmann AM
Eur Neuropsychopharmacol; 2008 Aug; 18(8):569-77. PubMed ID: 18544469
[TBL] [Abstract][Full Text] [Related]
16. Development and bioavailability assessment of ramipril nanoemulsion formulation.
Shafiq S; Shakeel F; Talegaonkar S; Ahmad FJ; Khar RK; Ali M
Eur J Pharm Biopharm; 2007 May; 66(2):227-43. PubMed ID: 17127045
[TBL] [Abstract][Full Text] [Related]
17. N-antipyrine-3, 4-dichloromaleimide, an effective cyclic imide for the treatment of chronic pain: the role of the glutamatergic system.
Quintão NL; da Silva GF; Antonialli CS; de Campos-Buzzi F; Corrêa R; Filho VC
Anesth Analg; 2010 Mar; 110(3):942-50. PubMed ID: 20185671
[TBL] [Abstract][Full Text] [Related]
18. Design of fenofibrate microemulsion for improved bioavailability.
Hu L; Wu H; Niu F; Yan C; Yang X; Jia Y
Int J Pharm; 2011 Nov; 420(2):251-5. PubMed ID: 21907776
[TBL] [Abstract][Full Text] [Related]
19. Solid dispersions based on inulin for the stabilisation and formulation of delta 9-tetrahydrocannabinol.
van Drooge DJ; Hinrichs WL; Wegman KA; Visser MR; Eissens AC; Frijlink HW
Eur J Pharm Sci; 2004 Mar; 21(4):511-8. PubMed ID: 14998582
[TBL] [Abstract][Full Text] [Related]
20. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial.
Rog DJ; Nurmikko TJ; Young CA
Clin Ther; 2007 Sep; 29(9):2068-79. PubMed ID: 18035205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
